1. Agent: Chlamydia trachomatis.
2. Identification:
a. Symptoms: A sexually transmitted
primarily as urethritis and in females as
3. Incubation: Poorly defined, probably 7-14
Complications of male urethral infections include epididymitis, and
4. Reservoir: Humans.
5. Source: Genital secretions from infected
inflammation and mucopurulent discharge. Some women with 6. Transmission: Sexual activity; perinatal uncomplicated cervical infection
transmission from genital tract of mother
7. Communicability: People should be
considered infectious until 7 days after
8. Specific Treatment
a. Adults and Adolescents:
conjunctivitis, occurring 5-12 days after
four times a day for 7 days.**
b. Infant Treatment: ** Pregnant women – all pregnant women
b. Differential Diagnosis: Clinical
need to return for repeat testing 3 weeks
manifestations may be after treatment to ensure therapeutic cure.
CDC’s Sexually Transmitted Disease
9. Immunity: Susceptibility is general. No
c. Diagnosis: Chlamydial urogenital REPORTING PROCEDURES
3. Due to high rates of re-infection, re-testing
Report within 1 week of identification of case
or suspected case (Title 17, Section 2500,
4. Annual screening is recommended for all
sexually active teens and young adults up
CONTROL OF CASE & CONTACTS Isolation:
Universal precautions as 5. Presumptive treatment of partners is
appropriate for clinical settings. Appropriate
noninfectious. Patients should refrain from
sexual intercourse for 7 days after treatment
to prevent ongoing transmission to others. To
screening of adolescent and young adults
avoid re-infection abstain from sex with
previous sexual partner(s) until 7 days after
DIAGNOSTIC PROCEDURES Concurrent disinfection: Care in disposal of
San Joaquin County Public Health Laboratory
services are available. Refer to the Laboratory
CONTACTS:
Sex partners should be evaluated, tested and
For more detail on diagnosis and treatment of
treated if they had sexual contact with the
chlamydia and other STDs see the CDC’s
patient during the 60 days preceding onset of
Sexually Transmitted Disease Treatment
symptoms or of the date of diagnosis if the
Guidelines 2006 (MMWR, Aug 4, 2006; Vol. 55, RR-11).
treatment of sexual partners is recommended.
evaluated and treated even if the time of the
Mothers of infants diagnosed with chlamydia
and the sex partners of these mothers should
Neonates born to mothers with an untreated
chlamydia infection should be monitored to
ensure prompt treatment if infection develops.
PREVENTION-EDUCATION
1.
Patients should refrain from sexual intercourse for 7 days after both the patient and current sexual partners have completed treatment.
2. Pregnant women – all pregnant women
must return for repeat testing 3 weeks after treatment to ensure therapeutic cure.
Aultman Blood Center Donor Eligibility This list is not complete. Medical professionals are available at each blood collection center and details of each donor's health and activities are discussed in a confidential setting prior to blood donation. The final determination of eligibility is made at that time. Some donor eligibility rules are specified by the Food and Drug Administration for eve
Rabbit anti-CD163 Cat. No. and Size: 503-3964 : 1 ml rabbit monoclonal antibody purified by protein A/G in PBS/1% BSA buffer pH 7.6 with less than 0.1% sodium azide. 503-3961 : 7.0 ml pre-diluted rabbit monoclonal antibody purified by protein A/G in TBS/1% BSA buffer pH 7.6 with less than 0.1% sodium azide. Intended Use: For research use only. Not for use in